Financial Summary

Adaptimmune Therapeutics PLC  (ADAP)  $4.52    (%)

  • Symbol
    ADAP
    Price
    4.52$
    Beta
    2.26812
    Volume Avrg.
    1045392
    Market Cap
    698841730
    Last Div
    0
    Range
    0.709-13.4
    Changes
    -0.01
    Changes Percentage
    Exchange
    Nasdaq Global Select
    Industry
    Biotechnology
    Ceo
    Mr. Adrian Rawcliffe
    Sector
    Healthcare

About company

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. The company is headquartered in Abingdon, Oxfordshire and currently employs 430 full-time employees. The firm is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The firm has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The firm engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The firm is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. The company has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.


Income Statement

Year20192018201720162015201420132012201120102009
Revenue260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess34462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense3576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses10481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs65737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income55256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics11.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds11.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares3.042.742.432.2121.8211.342.63000
Gross margins0.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.210.220.210.210.230.220.220.270.240.210.19
EBITDA76477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT6393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.210.220.210.210.230.220.220.270.240.210.19